Debiopharm
WE DEVELOP FOR PATIENTS

MEDIA FACT SHEET

We develop tomorrow's standard of care
To cure cancer and infectious diseases
And to improve patient quality of life

1. Debiopharm in short

Debiopharm is an innovation-focused, Swiss biopharmaceutical company that aims to develop innovative therapies to target high unmet medical needs in oncology and infection diseases. We establish partnerships with academic, biotech, and pharmaceutical institutions to bridge the gap between disruptive discovery products and international patient reach. We seek out and identify high-potential compounds for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally. Our ultimate purpose is to develop tomorrow's standard of care to cure cancer and infectious diseases and to improve patient quality of life.

2. Company history

Debiopharm was created over 40 years ago by Dr. Rolland-Yves Mauvernay, who was convinced that many useful therapeutic products were abandoned before reaching their full potential. He therefore launched a unique business model whereby Debiopharm in-licenses innovative compounds, adds value and finances their development into medicines and then seeks a commercialization partner for out-licensing. Today, Debiopharm consists of a group of three companies, led by his son Thierry Mauvernay: Debiopharm International (DPI), Debiopharm Research & Manufacturing (DPRM), and Debiopharm Innovation Fund (DPIF). The group counts over 400 employees with a broad range of expertise, who are active in drug development, drug manufacturing, investment in digital health and smart data start-ups.

3. Debiopharm - Success stories

These two oncology products sold worldwide showcase Debiopharm's success in developing efficient treatments for patients.

The GnRH agonist analogue triptorelin, with international brand names including Decapeptyl®/Trelstar®/Pamorelin®/Triptodur®, is a standard-of-care treatment for advanced prostate cancer and an emerging therapy for endometriosis, in-vitro fertilization programs, uterine fibroids, precocious puberty. This product was the first worldwide registered sustained release formulation of a gonadotropin releasing hormone (GnRH) agonist in 1986 and is marketed throughout the world through our international alliance partnerships. More information

The Platinum-based chemotherapy oxaliplatin, marketed under the brand names Eloxatin®/Elplat®/Dacotin®/Dacplat®, is a diaminocyclohexane (DACH) platin, for the treatment of colorectal cancer. Combination of oxaliplatin with 5-FU and leucovorin (FOLFOX) allowed to more than double the survival of patients with metastatic disease. Since its approval in the 2000's, it has become a worldwide standard treatment in metastatic colorectal cancer and in adjuvant settings has significantly increased the number of patients cured. More information

Debio 1143 - phase III – oncology
Debio 1143 or Xevinapant is under an exclusive license agreement with Merck for product development and commercialization. It is a potent, orally available, inhibitor of IAPs for the treatment of head and neck cancer. More information

4. Debiopharm – Oncology and Antibiotic Pipeline

With patients in mind and to continue providing treatments, Debiopharm has 18 projects in development in its pipeline in its specialty areas including oncology, infectious diseases, and antibody-drug conjugate (ADC) drug technology. Here is a selection of compounds in development for the following indications: DNA damage response (DDR), radiotherapy, ADC linkers, and antibiotics. Full pipeline

Debio 0123 - phase I - oncology
Debio 0123 is a Wee1 kinase inhibitor currently in phase I research for the treatment of refractory solid tumors. In development to help overcome treatment resistance to current therapies, the compound works by preventing cancer cells to arrest or repair DNA damage, thus disrupting DNA damage response and triggering programmed cell death or permanent cell-cycle arrest, which is a potential anti-tumoral mode of action. More information

Debio 0432 – preclinical - oncology
Debio 0432, a small molecule USP1 inhibitor oncology program targeting a novel DNA damage repair (DDR) pathway, is in pre-clinical research to become a therapy that responds to the unmet needs of cancer patients.

Debio 0228 – phase I - oncology
Debio 0228 is part of a theranostic pair radioligand program targeting the CA IX surface protein. It is designed to selectively destroy certain tumor cells resistant to therapy. It will be developed using a combination of diagnostic and therapeutic features with the same compound, allowing the pre-identification of patients who have the receptors necessary to respond to the targeted radiotherapy. More information

Debio 0532 – preclinical - oncology
Debio 0532 is a program integrating Debiopharm's innovative linker technologies, Multilink™ and AbYlink™, to create innovative antibody drug conjugates (ADCs). These ADCs will be developed with capacity to target tumor-specific antigens to fight cancers with high unmet need, including those tumor types expressing HER2/HER3.

Multilink™ - Drug delivery technology
Debiopharm Research & Manufacturing has developed a linker platform: Multilink™, an innovative technology that allows the loading of multiple payloads on an antibody, suited for ADC technologies. It provides a highly efficient and selective drug release and a potential increased therapeutic window. Debio 1562M, also in development by Debiopharm leverages Multilink™ technology.

Debio 1450 - phase III for ABSSI & phase II for bone and joint infections
Debio 1450 or afabicin is a pathogen-specific antibiotic in development for the treatment of bone and joint infections, as well as acute bacterial skin and skin structure infections (ABSSSI). Debio 1450, a fabI inhibitor, has a unique anti-stapylococcal mechanism of action with pathogen-specific properties, providing a promising investigative therapy against hard-to-treat staphylococci infections. More information

5. Debiopharm Business Model

Debiopharm is a privately owned, unlisted biopharmaceutical company with the capability to finance the development of the candidates we in-license.

Debiopharm bridges the gap between disruptive discovery products and international patient reach. How? By identifying high-potential discovery or early-stage compounds in for in-licensing at universities and biotechs worldwide. Once identified, Debiopharm forms a partnership to in-licensing and then adds value to the in-licensed compound by conducting smart clinical development, from candidate to clinical phase II stage.

Decisions to in-license and develop specific drug candidates are based on science. Our qualified team of scientists rigorously evaluate the potential of each candidate and the benefit to patients before they are taken in for development. Ultimately Debiopharm selects large pharmaceutical commercialization partners to maximize access of the commercialized drugs to as many patients as possible across the globe. Partners include universities, biotech, and big pharma.

Additional information about Debiopharm
Website / LinkedIn / Facebook / Twitter / YouTube
Contact us